Navigation Links
Frost & Sullivan Recognizes Strategic Healthcare Programs for Best Practices in Focused Innovation
Date:2/17/2009

he data show comparisons between telemonitored and non-telemonitored patients.

SHP's technology integrates with over 30 different types of software vendors including healthcare majors such as Philips, Honeywell HomMed, McKesson, and Viterion. Two components that really make this technology unique and elegant are its real-time capability and ease of customization. The real-time capability and the customized data queries and benchmarks keep information relevant.

"In the end, all of these components seem to be focused around one common goal, optimizing the business and clinical performance for the home healthcare industry, and despite the daunting undertaking this goal represents, SHP seems to be well on its way toward this task," concludes Bujnoch.

For providing demand-oriented superior technology that has penetrated a mature and highly competitive healthcare market, SHP is the worthy recipient of the 2009 North American Award for Growth Enabling Technology for remote patient monitoring. Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in new product development and launch within its industry. The recipient company has shown innovation by launching a broad line of emerging products or technologies.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Strategic Healthcare Programs, L.L.C.

Strategic Healthcare Programs (SHP) is an award-winning innovator in real-time decision s
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Frost & Sullivan Says, Innovative Therapies Needed to Deal With the Rapid Spread of Cancer in Europe
2. Frost & Sullivan Helps You Know Your End-Market: Medical Trends Impacting the Chemicals and Materials Markets
3. Frost & Sullivan - Consumer Preference for Healthy Bakery
4. Frost & Sullivan Finds Compliance Requirements Drive the Healthcare Security Boom
5. Frost & Sullivan Bestows Product Line Strategy Leadership Award to VTS Medical Systems, LLC
6. Frost & Sullivan Forecasts Increased Demand for Portable and PC-based Ultrasound Units in Eastern Europe
7. Verified Physicians a Must for Ensuring Quality Data From Online Surveys, Finds Frost & Sullivan
8. Ready-To-Use Products Spur the European Tissue Sealants and Topical Hemostats Markets, Says Frost & Sullivan
9. Frost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters - An Attractive Future?
10. VTS Medical Systems, LLC Awarded Frost & Sullivan Excellence in Healthcare, Product Line Strategy Leadership Award for 2009
11. Horphag Research Receives 2008 Frost & Sullivan North American Health Ingredients Excellence In Research Award
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Pennsylvania Department of Health Launches Spanish Language Smoking Cessation Resource Web Site 47984 1Pennsylvania Department of Health Launches Spanish Language Smoking Cessation Resource Web Site 47984 2Illness and Medical Bills Linked to Nearly Two Thirds of All Bankruptcies 47982 1Illness and Medical Bills Linked to Nearly Two Thirds of All Bankruptcies 47982 2Illness and Medical Bills Linked to Nearly Two Thirds of All Bankruptcies 47982 3Illness and Medical Bills Linked to Nearly Two Thirds of All Bankruptcies 47982 4Prize4Life and the Alzheimer Research Forum Announce Launch of New Web Portal for ALS Research 47980 1Prize4Life and the Alzheimer Research Forum Announce Launch of New Web Portal for ALS Research 47980 2Prize4Life and the Alzheimer Research Forum Announce Launch of New Web Portal for ALS Research 47980 3